目的 系統(tǒng)評價異甘草酸鎂治療抗結核藥物所致肝損害的療效和安全性。方法 檢索PubMed、EMbase、Cochrane圖書館、Medline、中國學術期刊全文數(shù)據庫（CNKI）、中國生物醫(yī)學文獻數(shù)據庫（CBM）、萬方數(shù)據庫和維普數(shù)據庫，收集國內外關于異甘草酸鎂治療抗結核藥致肝損害的臨床隨機對照研究（RCTs），評價納入研究的質量并提取數(shù)據，使用RevMan 5.3軟件進行Meta-分析。結果 共納入14篇RCTs，包括1 202名抗結核藥致肝損害患者。Meta-分析結果顯示：異甘草酸鎂在治療抗結核藥致肝損害總有效率[RR=1.38，95% CI （1.24，1.54），P<0.000 01]、降低丙氨酸氨基轉移酶（ALT）[MD=-25.98，95% CI （-34.68，-17.29），P<0.000 01]、天冬氨酸氨基轉移酶（AST）[MD=-20.21，95% CI （-24.49，-15.93），P<0.000 01]、總膽紅素（TB）[MD=-9.92，95% CI （-16.41，-3.43），P=0.003]、堿性磷酸酶（ALP）[MD=-13.91，95% CI （-26.03，-1.79），P=0.02]方面均優(yōu)于對照組，差異有統(tǒng)計學意義，同時不良反應發(fā)生率低于對照組[RR=0.51，95% CI （0.27，0.96），P=0.04]。結論 異甘草酸鎂治療抗結核藥致肝損害臨床療效較好，可顯著降低患者血清ALT、AST、TB和ALP水平，同時具有較高安全性，但本研究納入文獻多為較低質量的小樣本研究，尚需更多高質量、大樣本的隨機對照試驗進一步支持。

Objective To evaluate the efficacy and safety of magnesium isoglycyrrhizinate in the treatment of liver injury caused by anti-tuberculosis drugs.Methods PubMed,EMbase,Cochrane Database,Medline,CNKI,the Chinese Biomedical Database (CBM),Wanfang Database and WIP Database were searched to collecte the randomized controlled trials (RCTs) on liver injury patients caused by anti-tuberculosis drugs treated with magnesium isoglycyrrhizin.After screening the literatures,the quality of the included studies and extracted data was evaluated by using the RevMan 5.3 software for meta-analysis.Results A total of 14 RCTs were selected,including 1 202 patients with liver injury caused by anti-tuberculosis drugs.The total effective rate[RR=1.38,95% CI (1.24,1.54),P< 0.000 01],the reduced ALT[MD=-25.98,95% CI (-34.68),-17.29),P< 0.000 01],AST[MD=-20.21,95% CI (-24.49,-15.93),P< 0.000 01],TB[MD=-9.92,95% CI (-16.41,-3.43),P=0.003],ALP[MD=-13.91,95% CI (-26.03,-1.79),P=0.02]were superior to the control group,the difference was statistically significant,and the incidence of adverse reactions was lower than that of the control group[RR=0.51,95% CI (0.27,0.96),P=0.04].Conclusion Magnesium glycyrrhizinate has a good clinical effect in the treatment of liver injury caused by anti-tuberculosis drugs,which can significantly reduce the serum levels of ALT,AST,TB and ALP,and has a higher safety.However,the less quantity of samples,more high-quality and large-sample RCTs are needed to further support.